Pfizer's Xalkori lung-cancer drug performs well in another Phase III

Pfizer's (PFE) Xalkori (Crizotinib) treatment met the main goal of a Phase III trial of untreated patients with a certain form of lung cancer by "significantly prolonging progression-free survival (PFS)" when compared with standard chemotherapy.

The study, called Profile 1014, is the second positive global Phase III test that evaluated Xalkori against chemotherapy.

Xalkori has already been authorized to treat previously treated patients. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs